Within the depths of Earth lies an invisible frontier of
life—caves. Because they are difficult to access, the
genetic profiles of cave microbiomes have remained
poorly understood. Despite limited access to sunlight,
nutrients, and oxygen, cave microbes have formed complex communities with unique metabolic strategies that are well-adapted to their extreme environment. Now, scientists are trying to understand how these biological pathways might help us produce new drugs.
A recent study published in Scientific Data led by Huihong
Li (GSAS ‘28), a Yale student pursuing a master’s degree in
bioinformatics, revealed that the biological machinery of cave
microbes is astonishingly diverse and powerful. The study
used genetic material from thirty-seven caves worldwide to
construct nearly 2,000 microbial genomes. Among these, the researchers found 1,858 bacteria and 121 archaea, ninety-nine percent of which appear completely different from all known species.
Additionally, researchers constructed a bioinformatics
pipeline to sequence genomic data and predict enzymatic
activities of gene products. Remarkably, ninety-eight percent
of genomes contained biosynthetic gene clusters, groups
of two or more genes that can work together to produce
complex biomolecules. At the same time, ninety-five percent
of genomes were predicted to contain antibiotic-resistant
genes. This intricate biological machinery could be useful to
scientists as they search for new therapeutics. “We might be
able to recombine and test those genes to produce bioproducts
on a large scale,” Li said. Sometimes, the journey of biomedical
discovery leads us to dive deep into unfamiliar places.